A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Authors
Keywords
-
Journal
VirusDisease
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-02
DOI
10.1007/s13337-022-00755-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
- (2021) Saborni Chakraborty et al. ADVANCED DRUG DELIVERY REVIEWS
- COVID-19 vaccines: where we stand and challenges ahead
- (2021) Guido Forni et al. CELL DEATH AND DIFFERENTIATION
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- BNT162b2 mRNA COVID-19 Vaccine: First Approval
- (2021) Yvette N. Lamb DRUGS
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
- (2021) Jianmin Zuo et al. NATURE IMMUNOLOGY
- Neutralizing Activity of BNT162b2-Elicited Serum
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective
- (2021) Colin D. Funk et al. Viruses-Basel
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
- (2021) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees
- (2021) Pragya D Yadav et al. CLINICAL INFECTIOUS DISEASES
- COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
- (2021) Rebecca Forman et al. HEALTH POLICY
- Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
- (2021) Gajanan N Sapkal et al. JOURNAL OF TRAVEL MEDICINE
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Five reasons why COVID herd immunity is probably impossible
- (2021) Christie Aschwanden NATURE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
- (2021) Yingzhu Li et al. ACS Central Science
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
- (2021) Eric Yuk Fai Wan et al. LANCET INFECTIOUS DISEASES
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
- (2021) Ugur Sahin et al. NATURE
- mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
- (2021) Hiam Chemaitelly et al. NATURE MEDICINE
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covaxin
- (2021) Dalmeet Singh Chawla NEW SCIENTIST
- A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development
- (2021) Zainalabideen A. Abdulla et al. Pathogens
- Side effects and perceptions following Sinopharm COVID-19 vaccination
- (2021) Balsam Qubais Saeed et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
- (2020) Qihui Wang et al. CELL
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
- (2020) Ling Ni et al. IMMUNITY
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
- (2020) Lianpan Dai et al. CELL
- Lessons for COVID-19 Immunity from Other Coronavirus Infections
- (2020) Alan Sariol et al. IMMUNITY
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mutations Strengthened SARS-CoV-2 Infectivity
- (2020) Jiahui Chen et al. JOURNAL OF MOLECULAR BIOLOGY
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
- (2020) Kizzmekia S. Corbett et al. NEW ENGLAND JOURNAL OF MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccines for COVID-19: The current state of play
- (2020) Archana Koirala et al. Paediatric Respiratory Reviews
- Cellular immune responses to covid-19
- (2020) Herb F Sewell et al. BMJ-British Medical Journal
- The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
- (2020) Lea Skak Filtenborg Frederiksen et al. Frontiers in Immunology
- Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
- (2020) Eriko Padron-Regalado Infectious Diseases and Therapy
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
- (2020) Gregory A Poland et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging Concepts and Technologies in Vaccine Development
- (2020) Morgan Brisse et al. Frontiers in Immunology
- A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
- (2020) Omna Sharma et al. Frontiers in Immunology
- Coronaviruses in wild birds – A potential and suitable vector for global distribution
- (2020) Md. Mijanur Rahman et al. Veterinary Medicine and Science
- Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
- (2020) Lauren B. Rodda et al. CELL
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19 vaccines: delivering protective immunity
- (2020) Herb F Sewell et al. BMJ-British Medical Journal
- Covid-19: What do we know about the late stage vaccine candidates?
- (2020) Elisabeth Mahase BMJ-British Medical Journal
- COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies
- (2020) Kajal Rawat et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Efficacy, safety and immunogenicity of Live Attenuated Varicella Vaccine in healthy children in China: A double-blind, randomized, placebo-controlled clinical trial
- (2019) Baolin Hao et al. CLINICAL MICROBIOLOGY AND INFECTION
- Vaccine hesitancy and (fake) news: Quasi‐experimental evidence from Italy
- (2019) Vincenzo Carrieri et al. HEALTH ECONOMICS
- Materials for non-viral intracellular delivery of messenger RNA therapeutics
- (2016) Kevin J. Kauffman et al. JOURNAL OF CONTROLLED RELEASE
- Protective CD8 T Cell-Mediated Immunity against Influenza A Virus Infection following Influenza Virus-like Particle Vaccination
- (2013) E. A. Hemann et al. JOURNAL OF IMMUNOLOGY
- Virus-like particle-based human vaccines: quality assessment based on structural and functional properties
- (2013) Qinjian Zhao et al. TRENDS IN BIOTECHNOLOGY
- Virus-like particles in vaccine development
- (2010) António Roldão et al. Expert Review of Vaccines
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started